Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition
The study demonstrates that the dual GTP/GDP-bound KRASG12C inhibitor BBO-8520 outperforms the GTP-bound-only inhibitor sotorasib by more durably suppressing KRAS and PI3K-AKT signaling, revealing that targeting the RAS-PI3K interaction is a key strategy to overcome resistance and enhance tumor inhibition in KRASG12C-mutant lung cancer.